Cystic Fibrosis Pulmonary Infections: Lessons from Around the World

1. Front Matter

   Pages I-XVI

   PDF

2. Cystic Fibrosis Pulmonary Infections: General Aspects

   1. Viral, Fungal and Atypical Bacterial Infections in Cystic Fibrosis

      • Barbara Przyklenk, Adolf Bauernfeind

      Pages 1-11

   2. Pharmacokinetics of Antibacterials in Cystic Fibrosis

      • Fritz Sörgel, Martina Kinzig, Christoph Labisch, Martina Hofmann, Ulrich Stephan

      Pages 13-27

   3. Antimicrobial Pharmacotoxicity

      • Henry C. Farrar, Gregory L. Kearns

      Pages 29-50

   4. Microbial Resistance

      • Lisa Saiman, Alice Prince

      Pages 51-64

   5. Microbial Virulence and Pathogenesis in Cystic Fibrosis

      • Eshwar Mahenthiralingam, David P. Speert

      Pages 65-84

   6. Lung Transplantation

      • Brendan P. Madden, Margaret E. Hodson

      Pages 85-97

3. Cystic Fibrosis Pulmonary Infections: The International Perspective

   1. The General Approach to Cystic Fibrosis-Related Pulmonary Infection in the United States

      • Harris R. Stutman

      Pages 99-110

   2. The General Approach to Cystic Fibrosis Pulmonary Infection in Canada

      • Noni MacDonald, Mary Corey, Rod Morrison

      Pages 111-117

   3. Cystic Fibrosis in Latin America

      • C. N. Macri, O. H. Pivetta, A. Gentile, E. G. Cafferata, M. C. Luna

      Pages 119-138

   4. Pulmonary Infections in Venezuelan Patients with Cystic Fibrosis

      • Sonia Alvarez de Garcia Tuñon, Heberto Reyes

      Pages 139-148

   5. Pulmonary Infection in Cystic Fibrosis: The Australian Approach

      • Peter D. Phelan

      Pages 149-159

   6. Cystic Fibrosis in Japan

      • Y. Yamashiro, T. Shimizu, S. Oguchi, T. Shioya, S. Nagata, Y. Ohtsuka

      Pages 161-165

   7. The General Approach to Cystic Fibrosis Pulmonary Infection in Russia

      • Tatiana E. Guembitskaia, Ludmila A. Vishnyakova, Ludmila A. Zhelenina, Nikolai J. Kapranov

      Pages 167-173

   8. Cystic Fibrosis in Israel: Clinical and Microbiological Aspects

      • Eitan Kerem, Joseph Rivlin, Yaacov Yahav, Asher Tal, Amir Szeinberg, Itamar Shalit

      Pages 175-188

   9. The State of Cystic Fibrosis in Turkey

      • M. Demirkol, Z. Erturan, G. Hüner, T. Baykal, G. Kurdoğlu, Ö. Anğ

      Pages 189-201

   10. The General Approach to Cystic Fibrosis Pulmonary Infection in Greece

       • George S. Adam

       Pages 203-208

   11. The General Approach to Cystic Fibrosis Pulmonary Infection in Italy

       • Rita Padoan, Alessandra Pianaroli, Annamaria Giunta

       Pages 209-221

   12. The General Approach to Cystic Fibrosis Pulmonary Infection in Spain

       • Sira Carrasco, Fernando Baquero

       Pages 223-228

   13. Cystic Fibrosis in the Western Part of Germany: A General Review about Cystic Fibrosis Management

       • H.-G. Posselt

       Pages 229-238

Infection of the lower respiratory tract is a major determinant of the course of cystic fibrosis. Although numerous efforts have been made to elucidate the specific mechanisms predisposing the respiratory mucosa of cystic fibrosis patients to infection, so far no clinically relevant procedures for completely effective prevention or control of infection have resulted. Hence, in dealing with infections in cystic fibrosis, we continue to rely mainly on antimicrobials. Antiinfective measures are inseparably correlated with microbiology, and the quality of antiinfec­ tive therapy directly reflects the quality of microbial monitoring. Vali­ dated guidelines for microbiologic testing and antiinfective use need to be developed and made available to all health providers and their cystic fibrosis patients. Several years ago, the editors cochaired a symposium at the Interna­ tional Congress of Chemotherapy on the Global Perspectives of Micro­ biological and Clinical Infectious Diseases in Patients with Cystic Fibrosis. During this half-day symposium, the editors heard reports from several countries around the world with an alarming range of survival for patients with cystic fibrosis. This sent a dramatic message to us that the understanding of this disease, its diagnosis, management and prevention was different in various countries and that patients may be inconsistently served. That is how our journey began.

• Respiratory system
• infectious disease
• infectious diseases
• microbiology
• pediatrics

• Max von Pettenkofer-Institut, Ludwig-Maximilians-Universität, Munich, Germany

  Adolf Bauernfeind

• University of California at Irvine, Long Beach, USA

  Melvin I. Marks

• Long Beach Memorial Medical Center, Memorial Miller Children’s Hospital, Long Beach, USA

  Melvin I. Marks

• Department of Pediatrics, Faculty of Medicine, Göteborg University, Göteborg, Sweden

  Birgitta Strandvik

Policies and ethics